| Autor: |
Muthuvel, Gajanthan, Dauber, Andrew, Alexandrou, Eirene, Tyzinski, Leah, Andrew, Melissa, Hwa, Vivian, Backeljauw, Philippe |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Endocrinology & Metabolism; May2022, Vol. 107 Issue 5, pe2103-e2109, 7p |
| Abstrakt: |
Context: Patients with aggrecan (ACAN) deficiency present with dominantly inherited short stature, often with advanced skeletal maturation and premature growth cessation. There is a paucity of information on the effects of growth-promoting interventions. Objective: The aim of this study was to evaluate the efficacy and safety of recombinant human growth hormone (rhGH) therapy on linear growth in children with ACAN deficiency. Methods: Open-label, single-arm, prospective study at Cincinnati Children’s Hospital Medical Center. Ten treatment-naïve patients were recruited. Inclusion criteria were a confirmed heterozygous mutation in ACAN, age ≥2 years, prepubertal, bone age (BA) ≥chronological age (CA), and normal insulin-like growth factor I concentration. Treatment was with rhGH (50 µg/kg/day) over 1 year. Main outcomes measured were height velocity (HV) and change in (Δ) height SD score (HtSDS). Results: Ten patients (6 females) were enrolled with median CA of 5.6 years (range 2.4-9.7). Baseline median HtSDS was –2.5 (range –4.3 to –1.1). Median baseline BA was 6.9 years (range 2.5-10.0), with median BA/CA of 1.2 (range 0.9-1.5). Median pretreatment HV was 5.2 cm/year (range 3.8-7.1), increased to 8.3 cm/year (range 7.3-11.2) after 1 year of therapy (P = .004). Median ΔHtSDS after 1 year was +0.62 (range +0.35 to +1.39) (P = .002). Skeletal maturation did not advance inappropriately (median ΔBA/CA –0.1, P = .09). No adverse events related to rhGH were observed. Conclusion: Treatment with rhGH improved linear growth in a cohort of patients with short stature due to ACAN deficiency. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
